657.53

1.65% 10.66

After Hours: 656.71 -0.82 -0.12%

Regeneron Pharmaceuticals Inc (REGN)

Overview News Price History Option Chain Financials Why REGN Down? Discussions Forecast

Regeneron Pharmaceuticals Inc stock is traded at $657.53, with a volume of 688.28K. It is up +1.65% in the last 24 hours and up +12.74% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Previous Close:

$646.87

Open:

$650.35

24h Volume:

688.28K

Relative Volume:

0.67

Market Cap:

$68.50B

Revenue:

$14.25B

Net Income/Loss:

$4.58B

P/E Ratio:

15.74

EPS:

41.7701

Net Cash Flow:

$3.88B

1W Performance:

+0.88%

1M Performance:

+12.74%

6M Performance:

+17.22%

1Y Performance:

-20.25%

1-Day Range:

$640.99

$658.21

1-Week Range:

$625.14

$658.21

52-Week Range:

$476.49

$834.42

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name

Regeneron Pharmaceuticals Inc

Sector

Healthcare (1134)

Industry

Biotechnology (636)

Phone

(914) 847-7000

Address

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Employee

15,207

Twitter

@regeneron

Next Earnings Date

2025-08-01

Latest SEC Filings

REGN's Discussions on Twitter

Compare REGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REGN Regeneron Pharmaceuticals Inc	657.53	67.99B	14.25B	4.58B	3.88B	41.77
VRTX Vertex Pharmaceuticals Inc	409.47	105.61B	11.74B	3.68B	3.34B	14.19
ALNY Alnylam Pharmaceuticals Inc	442.70	58.19B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	854.65	52.40B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	189.70	39.60B	447.02M	-1.18B	-906.14M	-6.1812

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight
May-14-25	Upgrade	Citigroup	Neutral → Buy
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform
Jan-16-25	Downgrade	UBS	Buy → Neutral
Dec-10-24	Resumed	BofA Securities	Underperform
Nov-15-24	Initiated	Wolfe Research	Outperform
Nov-14-24	Initiated	Citigroup	Neutral
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-12-24	Initiated	Bernstein	Outperform
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Nov-09-23	Initiated	Deutsche Bank	Hold
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy
Aug-21-23	Reiterated	Oppenheimer	Perform
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-24-23	Upgrade	Jefferies	Hold → Buy
Mar-23-23	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-30-23	Upgrade	Cowen	Market Perform → Outperform
Jan-20-23	Upgrade	JP Morgan	Neutral → Overweight
Oct-26-22	Downgrade	Raymond James	Mkt Perform → Underperform
Oct-17-22	Downgrade	Evercore ISI	Outperform → In-line
Sep-09-22	Upgrade	Jefferies	Underperform → Hold
Sep-09-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-25-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
Jun-06-22	Initiated	Jefferies	Underperform
May-23-22	Initiated	SVB Leerink	Outperform
Jan-05-22	Downgrade	BofA Securities	Neutral → Underperform
Jan-03-22	Upgrade	Bernstein	Mkt Perform → Outperform
Dec-15-21	Downgrade	Bernstein	Outperform → Mkt Perform
Dec-09-21	Resumed	Wells Fargo	Overweight
Dec-07-21	Resumed	Cowen	Market Perform
Dec-06-21	Initiated	Goldman	Buy
Nov-19-21	Resumed	BMO Capital Markets	Outperform
Nov-05-21	Downgrade	The Benchmark Company	Buy → Hold
Jun-29-21	Initiated	H.C. Wainwright	Buy
Jan-25-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jan-13-21	Upgrade	The Benchmark Company	Hold → Buy
Jan-08-21	Upgrade	Citigroup	Neutral → Buy
Oct-05-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Aug-20-20	Downgrade	The Benchmark Company	Buy → Hold
Jul-09-20	Upgrade	SunTrust	Hold → Buy
May-26-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Apr-28-20	Downgrade	Citigroup	Buy → Neutral
Apr-17-20	Upgrade	The Benchmark Company	Hold → Buy
Apr-08-20	Initiated	The Benchmark Company	Hold
Mar-31-20	Initiated	Wolfe Research	Peer Perform
Feb-27-20	Initiated	Barclays	Overweight
Feb-26-20	Upgrade	Canaccord Genuity	Hold → Buy
Feb-26-20	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-25-20	Upgrade	Jefferies	Hold → Buy
Feb-11-20	Upgrade	Argus	Hold → Buy
Dec-24-19	Initiated	Raymond James	Mkt Perform
Dec-16-19	Downgrade	Evercore ISI	Outperform → In-line
Dec-13-19	Upgrade	Credit Suisse	Neutral → Outperform
Nov-12-19	Initiated	SunTrust	Hold
Nov-07-19	Upgrade	Citigroup	Neutral → Buy
Oct-17-19	Resumed	BofA/Merrill	Neutral
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy

View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

01:52 AM

Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $660.00 Price Target at UBS Group - MarketBeat

01:52 AM

10:50 AM

Regeneron Announces Positive Phase 2 Trial Results for Factor XI Antibodies in Total Knee Replacement Patients - Quiver Quantitative

10:50 AM

10:46 AM

Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet - GlobeNewswire Inc.

10:46 AM

10:00 AM

How Regeneron Pharmaceuticals Inc. stock responds to policy changesBear Alert & Fast Moving Stock Trade Plans - newser.com

10:00 AM

09:57 AM

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study - MarketScreener

09:57 AM

09:10 AM

Harvest Portfolios Group Inc. Acquires 16,076 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

09:10 AM

06:59 AM

Resona Asset Management Co. Ltd. Has $20.82 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

06:59 AM

04:55 AM

How strong is Regeneron Pharmaceuticals Inc. stock balance sheetJuly 2025 Technicals & Safe Entry Trade Reports - newser.com

04:55 AM

02:52 AM

Assessing Regeneron Pharmaceuticals (REGN) Valuation Following Recent Share Price Rebound - simplywall.st

02:52 AM

02:38 AM

What data driven models say about Regeneron Pharmaceuticals Inc.’s futureJuly 2025 Retail & Consistent Profit Trade Alerts - newser.com

02:38 AM

Nov 07, 2025

UBS Raises Regeneron Pharmaceuticals (REGN) Price Target to $660 - GuruFocus

Nov 07, 2025

Can a trend reversal in Regeneron Pharmaceuticals Inc. lead to recovery2025 Technical Overview & Growth Focused Stock Reports - newser.com

Nov 07, 2025

REGN: Regeneron and Sanofi Report Positive Dupixent Trial Results - GuruFocus

Nov 07, 2025

How robust is Regeneron Pharmaceuticals Inc. (RGO) stock financial positionJuly 2025 Big Picture & High Accuracy Trade Signal Alerts - newser.com

Nov 07, 2025

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review - The Manila Times

Nov 07, 2025

Regeneron and Sanofi Announce Positive Phase 3 Results for Dupixent in Treating Allergic Fungal Rhinosinusitis, FDA Accepts Application for Priority Review - Quiver Quantitative

Nov 07, 2025

Dupixent shows significant improvement for allergic fungal rhinosinusitis By Investing.com - Investing.com Australia

Nov 07, 2025

Regeneron (NASDAQ: REGN): Dupixent cut 92% steroid/surgery risk in AFRS; Priority Review - Stock Titan

Nov 07, 2025

Sienna Gestion Grows Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Nov 07, 2025

Will earnings trigger a reversal in Regeneron Pharmaceuticals Inc.July 2025 Momentum & Reliable Intraday Trade Alerts - newser.com

Nov 07, 2025

Nov 06, 2025

Is Regeneron’s (REGN) ModeX Collaboration and Strong Q3 Earnings Shifting Its Antibody Growth Story? - simplywall.st

Nov 06, 2025

Can Regeneron Pharmaceuticals Inc. stock weather global recessionPortfolio Performance Report & Daily Profit Focused Stock Screening - newser.com

Nov 06, 2025

Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsJuly 2025 PostEarnings & Technical Confirmation Alerts - newser.com

Nov 06, 2025

Is Regeneron Pharmaceuticals Inc. trending in predictive chart modelsPortfolio Return Summary & Long-Term Capital Growth Ideas - newser.com

Nov 06, 2025

Is Regeneron Pharmaceuticals Inc. stock positioned for digital transformationQuarterly Trade Summary & Intraday High Probability Alerts - newser.com

Nov 06, 2025

United States Respiratory Disorders Market Info 2025 | Top - openPR.com

Nov 06, 2025

How Regeneron Pharmaceuticals Inc. (RGO) stock correlates with oil markets2025 Historical Comparison & Weekly High Return Stock Forecasts - fcp.pa.gov.br

Nov 06, 2025

Ellevest Inc. Buys 464 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Nov 06, 2025

News impact scoring models applied to Regeneron Pharmaceuticals Inc.Weekly Market Summary & Expert Approved Momentum Ideas - newser.com

Nov 06, 2025

Nov 05, 2025

What MACD signals say about Regeneron Pharmaceuticals Inc.July 2025 Selloffs & Weekly High Return Stock Forecasts - newser.com

Nov 05, 2025

Can Regeneron Pharmaceuticals Inc. stock continue upward trend2025 Buyback Activity & Long-Term Safe Investment Plans - fcp.pa.gov.br

Nov 05, 2025

Combining price and volume data for Regeneron Pharmaceuticals Inc.2025 EndofYear Setup & Daily Growth Stock Investment Tips - newser.com

Nov 05, 2025

Can Regeneron Pharmaceuticals Inc. stock hit record highs again2025 Breakouts & Breakdowns & Weekly High Potential Stock Alerts - newser.com

Nov 05, 2025

Can Regeneron Pharmaceuticals Inc. stock sustain revenue growth2025 Analyst Calls & Fast Gaining Stock Reports - fcp.pa.gov.br

Nov 05, 2025

Using fundamentals and technicals on Regeneron Pharmaceuticals Inc.July 2025 Pullbacks & Weekly Market Pulse Updates - newser.com

Nov 05, 2025

Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Nov 05, 2025

Assessing Regeneron After New Drug Pipeline Expansions and Double-Digit Share Price Decline - Yahoo Finance

Nov 05, 2025

Dillon & Associates Inc. Lowers Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Nov 05, 2025

Is Regeneron a Value Opportunity After Fresh FDA Approvals and 24% Price Drop? - simplywall.st

Nov 05, 2025

Can Regeneron Pharmaceuticals Inc. stock maintain operating marginsJuly 2025 Weekly Recap & Weekly Breakout Stock Alerts - newser.com

Nov 05, 2025

Bank of New York Mellon Corp Sells 41,629 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Nov 05, 2025